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Background
HIV-specific CD8+ T-cells in the peripheral blood dimin-
ish in most patients after the initiation of highly active
antiretroviral therapy (HAART). However, examples of de
novo appearance of HIV-specific CD8+ T-cells in patients
with long-term successful therapy have also been
described. The aim of our study was to determine the fre-
quency and absolute counts of Gag-specific CD8+ T-cells
in the peripheral blood of HIV-patients with more than 5
years of treatment-induced undetectable viremia and
compare it with non-symptomatic untreated chronically-
infected persons.
Materials and methods
The study enrolled 15 untreated HIV-patients (median
CD4 T-cells count 323.5 cells/µL, median percentage of
CD4+ T-cells 17.3%) and 15 HIV-patients who have main-
tained undetectable plasma viremia (<50 copies of HIV-1
RNA/mL) for more than 5 years (median time on HAART
6.7 years, range 5 to 7 years, median CD4+ T-cell count
544 cells/µL, median percentage of CD4+ T-cells 24.3%).
Percentages of Gag-specific CD8+ T-cells in the peripheral
blood of our patients were determined by using iTAg™
MHC class I tetramers (A*0201) specific for SLYNTVATL
(Beckman Coulter Immunomics Operations, USA) on
FC500 flow cytometer (Beckman Coulter, USA). Absolute
counts of Gag-specific CD8+ T-cells were determined by
using Flow-count Fluorospheres (Beckman Coulter, USA).
Results
Gag-specific CD8+ T-cells were detected in 12/15 (80%) of
untreated HIV-patients and in 9/15 (66%) of treated HIV-
patients with > 5 years of undetectable viremia. Percent-
ages of Gag-specific CD8+ T-cells in ranged between 0.1
and 1.1% in untreated patients and between 0.1–0.7% in
treated patients. Untreated HIV-patients had between 1
and 9 Gag-specific CD8 T-cells/µL of blood. HIV-patients
with more than 5 years of undetectable viremia had
between 1–6 Gag-specific CD8+ T-cells/µL of blood.
Conclusion
Gag-specific CD8+ T-cells are detectable in some patients
who have been successfully treated with HAART for more
than 5 years. The frequency and absolute counts of Gag-
specific CD8+ T-cells in patients with more than 5 years of
successful HAART are different compared with untreated
patients. These findings are relevant for the analysis of
immune reconstitution following long-term successful
HAART.
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